MedPage Today -- In selected patients with metastatic non-small cell lung cancer, the targeted therapy gefitinib (Iressa) significantly prolongs the period before the disease progresses, researchers said.
MedPage Today -- In selected patients with metastatic non-small cell lung cancer, the targeted therapy gefitinib (Iressa) significantly prolongs the period before the disease progresses, researchers said.
